|
1
|
Marchesini G, Bugianesi E, Forlani G,
Cerrelli F, Lenzi M, Manini R, Natale S, Vanni E, Villanova N,
Melchionda N and Rizzetto M: Nonalcoholic fatty liver,
steatohepatitis, and the metabolic syndrome. Hepatology.
37:917–923. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Schreuder TC, Verwer BJ, van Nieuwkerk CM
and Mulder CJ: Nonalcoholic fatty liver disease: an overview of
current insights in pathogenesis, diagnosis and treatment. World J
Gastroenterol. 14:2474–2486. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kotronen A and Yki-Järvinen H: Fatty
liver: a novel component of the metabolic syndrome. Arterioscler
Thromb Vasc Biol. 28:27–38. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Edmison J and McCullough AJ: Pathogenesis
of non-alcoholic steatohepatitis: human data. Clin Liver Dis.
11:75–104. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Marchesini G, Brizi M, Bianchi G,
Tomassetti S, Bugianesi E, Lenzi M, McCullough AJ, Natale S,
Forlani G and Melchionda N: Nonalcoholic fatty liver disease: a
feature of the metabolic syndrome. Diabetes. 50:1844–1850. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Varela-Rey M, Embade N, Ariz U, Lu SC,
Mato JM and Martinez-Chantar ML: Non-alcoholic steatohepatitis and
animal models: understanding the human disease. Int J Biochem Cell
Biol. 41:969–976. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nepokroeff CM, Lakshmanan MR and Porter
JW: Fatty-acid synthase from rat liver. Methods Enzymol. 35:37–44.
1975. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Targher G, Bertolini I, Rodella S, Zoppini
G, Lippi G, Day C and Muggeo M: Non-alcoholic fatty liver disease
is independently associated with an increased prevalence of chronic
kidney disease and proliferative/laser-treated retinopathy in type
2 diabetic patients. Diabetologia. 51:444–450. 2008. View Article : Google Scholar
|
|
9
|
Unger RH, Clark GO, Scherer PE and Orci L:
Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim
Biophys Acta. 1801:209–214. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lindor KD, Kowdley KV, Heathcote EJ,
Harrison ME, Jorgensen R, Angulo P, Lymp JF, Burgart L and Colin P:
Ursodeoxycholic acid for treatment of nonalcoholic steatosis
steatohepatitis: results of a randomized trial. Hepatology.
39:770–778. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sgro C and Escousse A: Side effects of
fibrates (except liver and muscle). Therapie. 46:351–354. 1991.(In
French).
|
|
12
|
Cha HW, Park MS and Park KM: Physiological
activities of Rubus coreanus Miquel. Korean J Food Sci Tech.
33:409–415. 2001.
|
|
13
|
Yang HM, Oh SM, Lim SS, Shin HK, Oh YS and
Kim JK: Antiinflammatory activities of Rubus coreanus depend
on the degree of fruit ripening. Phytother Res. 22:102–107.
2008.
|
|
14
|
Oh MS, Yang WM, Chang MS, Park W, Kim do
R, Lee HK, Kim WN and Park SK: Effect of Rubus coreanus on
sperm parameters and cAMP responsive element modulator (CREM)
expression in rat testes. J Ethnopharmacol. 114:463–467. 2007.
|
|
15
|
Lee MW: Phenolic compounds from the leaves
of Rubus coreanus. Yakhak Hoeji. 39:200–204. 1995.
|
|
16
|
Perry LM: Medicinal plants of east and
southeast Asia, attributed properties and uses. MIT press;
Cambridge, MA: pp. 346–356. 1980
|
|
17
|
Sohn DW, Kim HY, Kim SD, Lee EJ, Kim HS,
Kim JK, Hwang SY, Cho YH and Kim SW: Elevation of intracavernous
pressure and NO-cGMP activity by a new herbal formula in penile
tissues of spontaneous hypertensive male rats. J Ethnopharmacol.
120:176–180. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee YI, Choi SK, Yang JY, Cho JS and Kim
TH: Hepatoprotective activities of Rubus coreanus depends on
the degree of ripening. Natural Product Sciences. 15:156–161.
2009.
|
|
19
|
Lee YI, Whang KE, Cho JS, Ahn BM, Lee SB,
Dong MS and Kim TH: Rubus coreanus extract attenuates
acetaminophen induced hepatotoxicity; involvement of cytochrome
P450 3A4. Biomol Ther. 17:455–460. 2009. View Article : Google Scholar
|
|
20
|
Hwang JM, Cho JS, Kim TH and Lee YI:
Ellagic acid protects hepatocytes from damage by inhibiting
mitochondrial production of reactive oxygen species. Biomed
Pharmacother. 64:264–270. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kang EH, Kown TY, Oh GT, Park WF, Park SI,
Park SK and Lee YI: The flavonoid ellagic acid from a medicinal
herb inhibits host immune tolerance induced by the hepatitis B
virus-e antigen. Antiviral Res. 72:100–106. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kaul A and Khanduja KL: Plant polyphenols
inhibit benzoyl peroxide-induced superoxide anion radical
production and diacylglyceride formation in murine peritoneal
macrophages. Nutr Cancer. 35:207–211. 1999. View Article : Google Scholar
|
|
23
|
Folch J, Lees M and Sloane Stanley GH: A
simple method for the isolation and purification of total lipids
from animal tissues. J Biol Chem. 226:497–509. 1957.
|
|
24
|
Hulcher FH and Oleson WH: Simplified
spectrophotometric assay for microsomal 3-hydroxy-3-methylglutaryl
CoA reductase by measurement of coenzyme A. J Lipid Res.
14:625–631. 1973.
|
|
25
|
Markwell MA, McGroarty EJ, Bieber LL and
Tolbert NE: The subcellular distribution of carnitine
acyltransferases in mammalian liver and kidney. J Biol Chem.
248:3426–3432. 1973.PubMed/NCBI
|
|
26
|
Angulo P: Nonalcoholic fatty liver
disease. N Eng J Med. 346:1221–1231. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Dixon JB, Bhathal PS and O’Brien PE:
Nonalcoholic fatty liver disease: predictors of nonalcoholic
steatohepatitis and liver fibrosis in the severely obese.
Gastroenterology. 121:91–100. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zelcer N and Tontonoz P: Liver X receptors
as integrators of metabolic and inflammatory signaling. J Clin
Invest. 116:607–614. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
29
|
Horton JD, Goldstein JL and Brown MS:
SREBPs: Activators of the complete program of cholesterol and fatty
acid synthesis in the liver. J Clin Invest. 109:1125–1131. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhou G, Myers R, Li Y, Chen Y, Shen X,
Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N,
Hirshman MF, Goodyear LJ and Moller DE: Role of AMP-activated
protein kinase in mechanism of metformin action. J Clin Invest.
108:1167–1174. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu H, Li J, Zhao W, Bao L, Song X, Xia Y,
Wang X, Zhang C, Wang X, Yao X and Li M: Fatty acid synthase
inhibitors from Geum japonicum Thunb. var chinense.
Chem Biodivers. 6:402–410. 2009. View Article : Google Scholar
|
|
32
|
Meyer AS, Heinonen M and Frankel EN:
Antioxidant interactions of catechin, cyanidin, caffeic acid,
quercetin and ellagic acid on human LDL oxidation. Food Chem.
61:71–75. 1998. View Article : Google Scholar
|
|
33
|
Yu YM, Chang WC, Wu CH and Chiang SY:
Reduction of oxidative stress and apoptosis in hyperlipidemic
rabbits by ellagic acid. J Nutr Biochem. 16:675–681. 2005.
View Article : Google Scholar : PubMed/NCBI
|
